ADAMTS5 is a biomarker for prediction of response to infliximab in patients with rheumatoid arthritis

Kensei Tsuzaka, Yuka Itami, Tsutomu Takeuchi, Naoshi Shinozaki, Tetsuo Morishita

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Objective. To identify a biomarker for prediction of the response to infliximab (IFX) in patients with rheumatoid arthritis (RA), we focused on a disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS5) that seems to play a key role in aggrecan degradation in cartilage. Methods. Seventy-three randomly selected patients with active RAwere treated with IFX. Peripheral blood samples were collected at baseline and ADAMTS5 messenger RNA (mRNA) was quantified using real-time polymerase chain reaction. Results. Baseline ADAMTS5 mRNA levels in the good responder group were significantly lower (1.84 ± 1.56; p = 0.0408) than those in the moderate and nonresponder groups (2.54 ± 1.70) at 38 weeks of treatment with IFX. The 28-joint count Disease Activity Score (DAS28) at 38 weeks of treatment was significantly lower in the low ADAMTS5 group (2.30 ± 1.28; p = 0.0038) than in the high ADAMTS5 group (3.90 ± 1.61). The percentage reduction of the DAS28 was significantly higher in the low ADAMTS5 group (52.5% ± 28.8%; p = 0.0156) than in the high ADAMTS5 group (29.4% ± 27.2%). Further, the Δ Health Assessment Questionnaire (ΔHAQ) score, an estimate of the improvement in the HAQ score, at 38 weeks of treatment was significantly higher in the low ADAMTS5 group (1.18 ± 0.60; p = 0.0102) than in the high ADAMTS5 group (0.21 ± 0.78). The positive predictive value of a low baseline ADAMTS5 level for predicting good response and remission (DAS28 < 2.6 at 38 weeks) was 90.0% and 70.0%, respectively. Conclusion. The baseline ADAMTS5 mRNA level is a candidate biomarker for prediction of the response to IFX in patients with RA. The Journal of Rheumatology

Original languageEnglish
Pages (from-to)1454-1460
Number of pages7
JournalJournal of Rheumatology
Volume37
Issue number7
DOIs
Publication statusPublished - 2010 Jul

Fingerprint

Cartilage Oligomeric Matrix Protein
Disintegrins
Metalloproteases
Rheumatoid Arthritis
Biomarkers
Messenger RNA
Infliximab
Aggrecans
Joint Diseases
Health
Rheumatology
Cartilage
Real-Time Polymerase Chain Reaction

Keywords

  • ADAMTS aggrecanase
  • Arthritis
  • Biomarkers
  • Infliximab
  • Rheumatoid

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

ADAMTS5 is a biomarker for prediction of response to infliximab in patients with rheumatoid arthritis. / Tsuzaka, Kensei; Itami, Yuka; Takeuchi, Tsutomu; Shinozaki, Naoshi; Morishita, Tetsuo.

In: Journal of Rheumatology, Vol. 37, No. 7, 07.2010, p. 1454-1460.

Research output: Contribution to journalArticle

Tsuzaka, Kensei ; Itami, Yuka ; Takeuchi, Tsutomu ; Shinozaki, Naoshi ; Morishita, Tetsuo. / ADAMTS5 is a biomarker for prediction of response to infliximab in patients with rheumatoid arthritis. In: Journal of Rheumatology. 2010 ; Vol. 37, No. 7. pp. 1454-1460.
@article{fbd98f9ed7f444efb357a509b7c96083,
title = "ADAMTS5 is a biomarker for prediction of response to infliximab in patients with rheumatoid arthritis",
abstract = "Objective. To identify a biomarker for prediction of the response to infliximab (IFX) in patients with rheumatoid arthritis (RA), we focused on a disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS5) that seems to play a key role in aggrecan degradation in cartilage. Methods. Seventy-three randomly selected patients with active RAwere treated with IFX. Peripheral blood samples were collected at baseline and ADAMTS5 messenger RNA (mRNA) was quantified using real-time polymerase chain reaction. Results. Baseline ADAMTS5 mRNA levels in the good responder group were significantly lower (1.84 ± 1.56; p = 0.0408) than those in the moderate and nonresponder groups (2.54 ± 1.70) at 38 weeks of treatment with IFX. The 28-joint count Disease Activity Score (DAS28) at 38 weeks of treatment was significantly lower in the low ADAMTS5 group (2.30 ± 1.28; p = 0.0038) than in the high ADAMTS5 group (3.90 ± 1.61). The percentage reduction of the DAS28 was significantly higher in the low ADAMTS5 group (52.5{\%} ± 28.8{\%}; p = 0.0156) than in the high ADAMTS5 group (29.4{\%} ± 27.2{\%}). Further, the Δ Health Assessment Questionnaire (ΔHAQ) score, an estimate of the improvement in the HAQ score, at 38 weeks of treatment was significantly higher in the low ADAMTS5 group (1.18 ± 0.60; p = 0.0102) than in the high ADAMTS5 group (0.21 ± 0.78). The positive predictive value of a low baseline ADAMTS5 level for predicting good response and remission (DAS28 < 2.6 at 38 weeks) was 90.0{\%} and 70.0{\%}, respectively. Conclusion. The baseline ADAMTS5 mRNA level is a candidate biomarker for prediction of the response to IFX in patients with RA. The Journal of Rheumatology",
keywords = "ADAMTS aggrecanase, Arthritis, Biomarkers, Infliximab, Rheumatoid",
author = "Kensei Tsuzaka and Yuka Itami and Tsutomu Takeuchi and Naoshi Shinozaki and Tetsuo Morishita",
year = "2010",
month = "7",
doi = "10.3899/jrheum.091285",
language = "English",
volume = "37",
pages = "1454--1460",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "7",

}

TY - JOUR

T1 - ADAMTS5 is a biomarker for prediction of response to infliximab in patients with rheumatoid arthritis

AU - Tsuzaka, Kensei

AU - Itami, Yuka

AU - Takeuchi, Tsutomu

AU - Shinozaki, Naoshi

AU - Morishita, Tetsuo

PY - 2010/7

Y1 - 2010/7

N2 - Objective. To identify a biomarker for prediction of the response to infliximab (IFX) in patients with rheumatoid arthritis (RA), we focused on a disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS5) that seems to play a key role in aggrecan degradation in cartilage. Methods. Seventy-three randomly selected patients with active RAwere treated with IFX. Peripheral blood samples were collected at baseline and ADAMTS5 messenger RNA (mRNA) was quantified using real-time polymerase chain reaction. Results. Baseline ADAMTS5 mRNA levels in the good responder group were significantly lower (1.84 ± 1.56; p = 0.0408) than those in the moderate and nonresponder groups (2.54 ± 1.70) at 38 weeks of treatment with IFX. The 28-joint count Disease Activity Score (DAS28) at 38 weeks of treatment was significantly lower in the low ADAMTS5 group (2.30 ± 1.28; p = 0.0038) than in the high ADAMTS5 group (3.90 ± 1.61). The percentage reduction of the DAS28 was significantly higher in the low ADAMTS5 group (52.5% ± 28.8%; p = 0.0156) than in the high ADAMTS5 group (29.4% ± 27.2%). Further, the Δ Health Assessment Questionnaire (ΔHAQ) score, an estimate of the improvement in the HAQ score, at 38 weeks of treatment was significantly higher in the low ADAMTS5 group (1.18 ± 0.60; p = 0.0102) than in the high ADAMTS5 group (0.21 ± 0.78). The positive predictive value of a low baseline ADAMTS5 level for predicting good response and remission (DAS28 < 2.6 at 38 weeks) was 90.0% and 70.0%, respectively. Conclusion. The baseline ADAMTS5 mRNA level is a candidate biomarker for prediction of the response to IFX in patients with RA. The Journal of Rheumatology

AB - Objective. To identify a biomarker for prediction of the response to infliximab (IFX) in patients with rheumatoid arthritis (RA), we focused on a disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS5) that seems to play a key role in aggrecan degradation in cartilage. Methods. Seventy-three randomly selected patients with active RAwere treated with IFX. Peripheral blood samples were collected at baseline and ADAMTS5 messenger RNA (mRNA) was quantified using real-time polymerase chain reaction. Results. Baseline ADAMTS5 mRNA levels in the good responder group were significantly lower (1.84 ± 1.56; p = 0.0408) than those in the moderate and nonresponder groups (2.54 ± 1.70) at 38 weeks of treatment with IFX. The 28-joint count Disease Activity Score (DAS28) at 38 weeks of treatment was significantly lower in the low ADAMTS5 group (2.30 ± 1.28; p = 0.0038) than in the high ADAMTS5 group (3.90 ± 1.61). The percentage reduction of the DAS28 was significantly higher in the low ADAMTS5 group (52.5% ± 28.8%; p = 0.0156) than in the high ADAMTS5 group (29.4% ± 27.2%). Further, the Δ Health Assessment Questionnaire (ΔHAQ) score, an estimate of the improvement in the HAQ score, at 38 weeks of treatment was significantly higher in the low ADAMTS5 group (1.18 ± 0.60; p = 0.0102) than in the high ADAMTS5 group (0.21 ± 0.78). The positive predictive value of a low baseline ADAMTS5 level for predicting good response and remission (DAS28 < 2.6 at 38 weeks) was 90.0% and 70.0%, respectively. Conclusion. The baseline ADAMTS5 mRNA level is a candidate biomarker for prediction of the response to IFX in patients with RA. The Journal of Rheumatology

KW - ADAMTS aggrecanase

KW - Arthritis

KW - Biomarkers

KW - Infliximab

KW - Rheumatoid

UR - http://www.scopus.com/inward/record.url?scp=77954445754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954445754&partnerID=8YFLogxK

U2 - 10.3899/jrheum.091285

DO - 10.3899/jrheum.091285

M3 - Article

C2 - 20516019

AN - SCOPUS:77954445754

VL - 37

SP - 1454

EP - 1460

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 7

ER -